21st century natural product research and drug development and traditional medicines.
暂无分享,去创建一个
[1] A. Nunn,et al. Global tuberculosis drug development pipeline: the need and the reality , 2010, The Lancet.
[2] T. Wells. Natural products as starting points for future anti-malarial therapies: going back to our roots? , 2011, Malaria Journal.
[3] S. Klamt,et al. GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism , 2007, Genome Biology.
[4] F. Bucar,et al. Natural product isolation--how to get from biological material to pure compounds. , 2013, Natural product reports.
[5] John R Yates,et al. A Comprehensive Survey of the Plasmodium Life Cycle by Genomic, Transcriptomic, and Proteomic Analyses , 2005, Science.
[6] Jay D Keasling,et al. Engineering Escherichia coli for production of functionalized terpenoids using plant P450s. , 2007, Nature chemical biology.
[7] R. Witkamp,et al. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology , 2005, Phytotherapy research : PTR.
[8] Márcia M. Almeida-de-Macedo,et al. A global approach to analysis and interpretation of metabolic data for plant natural product discovery. , 2013, Natural product reports.
[9] Lorenz von Seidlein,et al. Artemisinin resistance: current status and scenarios for containment , 2010, Nature Reviews Microbiology.
[10] Leen Rigouts,et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology , 2006, BMC Microbiology.
[11] Changnan Zhao,et al. Cloning of artemisinin biosynthetic cDNAs and novel ESTs and quantification of low temperature-induced gene overexpression , 2008, Science in China Series C: Life Sciences.
[12] C. Saslis-Lagoudakis,et al. The Use of Phylogeny to Interpret Cross-Cultural Patterns in Plant Use and Guide Medicinal Plant Discovery: An Example from Pterocarpus (Leguminosae) , 2011, PloS one.
[13] Tran Van Thuy,et al. Ethnobotany/ethnopharmacology and mass bioprospecting: issues on intellectual property and benefit-sharing. , 2005, Journal of ethnopharmacology.
[14] B. Barrell,et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.
[15] D. Kell. Systems biology, metabolic modelling and metabolomics in drug discovery and development. , 2006, Drug discovery today.
[16] Jaques Reifman,et al. Quantitative Predictions of Binding Free Energy Changes in Drug-Resistant Influenza Neuraminidase , 2012, PLoS Comput. Biol..
[17] D. Wishart. Applications of Metabolomics in Drug Discovery and Development , 2008, Drugs in R&D.
[18] Yat T Tang,et al. Virtual screening for lead discovery. , 2011, Methods in molecular biology.
[19] David J Newman,et al. Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.
[20] R. Heinzen,et al. Host-microbe interaction systems biology: lifecycle transcriptomics and comparative genomics. , 2010, Future microbiology.
[21] Hong Wang,et al. Isolation and characterization of AaWRKY1, an Artemisia annua transcription factor that regulates the amorpha-4,11-diene synthase gene, a key gene of artemisinin biosynthesis. , 2009, Plant & cell physiology.
[22] Yuchun Wang,et al. Artemisinin: current state and perspectives for biotechnological production of an antimalarial drug , 2006, Applied Microbiology and Biotechnology.
[23] L. Mooney,et al. Substandard and Falsified Anti-Tuberculosis Drugs: A Preliminary Field Analysis , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[24] D. P. Briskin. Medicinal plants and phytomedicines. Linking plant biochemistry and physiology to human health. , 2000, Plant physiology.
[25] Pilho Kim,et al. PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.
[26] P A Cox,et al. The ethnobotanical approach to drug discovery. , 1994, Scientific American.
[27] J. Derisi,et al. The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum , 2003, PLoS biology.
[28] P. Newton,et al. A Major Genome Region Underlying Artemisinin Resistance in Malaria , 2012, Science.
[29] T. Cook,et al. Re-positioning the role of traditional, complementary and alternative medicine as essential health knowledge in global health: do they still have a role to play? , 2009, World health & population.
[30] D. K. Arrell,et al. Network Systems Biology for Drug Discovery , 2010, Clinical pharmacology and therapeutics.
[31] Fan Qu,et al. Review of current and "omics" methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms. , 2012, Journal of ethnopharmacology.
[32] Timothy S. Ham,et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.
[33] C. Barry,et al. The mechanism of action of PA-824 , 2009, Communicative & integrative biology.
[34] Janya Saenboonrueng,et al. New antimycobacterial and antimalarial 8,9-secokaurane diterpenes from Croton kongensis. , 2003, Journal of natural products.
[35] J. Vederas,et al. Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.
[36] P. Arsenault,et al. Trichomes + roots + ROS = artemisinin: regulating artemisinin biosynthesis in Artemisia annua L. , 2011, In Vitro Cellular & Developmental Biology - Plant.
[37] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[38] L. Hood,et al. Systems medicine: the future of medical genomics and healthcare , 2009, Genome Medicine.
[39] D. Lun,et al. Systems biology approaches to understanding mycobacterial survival mechanisms. , 2010, Drug discovery today. Disease mechanisms.
[40] Bonnie Berger,et al. MetaMerge: scaling up genome-scale metabolic reconstructions with application to Mycobacterium tuberculosis , 2012, Genome Biology.
[41] Samuel A. Assefa,et al. New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq , 2010, Molecular microbiology.
[42] J. Laughlin. Agricultural production of artemisinin--a review. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[43] L. Barat. Four malaria success stories: how malaria burden was successfully reduced in Brazil, Eritrea, India, and Vietnam. , 2006, The American journal of tropical medicine and hygiene.
[44] Denise E Kirschner,et al. Tuberculosis: global approaches to a global disease. , 2010, Current opinion in biotechnology.
[45] Chenfei Ma,et al. Metabolic fingerprinting investigation of Artemisia annua L. in different stages of development by gas chromatography and gas chromatography-mass spectrometry. , 2008, Journal of chromatography. A.
[46] Matthias Buck,et al. The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity , 2011 .
[47] J. Bayona,et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis , 2010, The Lancet.
[48] Jonathan E. Allen,et al. Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.
[49] Alexey Bochkarev,et al. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. , 2007, Molecular and biochemical parasitology.
[50] K. Andries,et al. Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.
[51] K. Hostettmann,et al. Twenty years of research into medicinal plants: Results and perspectives , 2002, Phytochemistry Reviews.
[52] M. Heinrich. Ethnopharmacy and natural product research—Multidisciplinary opportunities for research in the metabolomic age , 2008 .
[53] Esther F. Schmid,et al. Keynote review: Is declining innovation in the pharmaceutical industry a myth? , 2005, Drug discovery today.
[54] Gilles Clermont,et al. Bridging the gap between systems biology and medicine , 2009, Genome Medicine.
[55] Yansheng Zhang,et al. The Molecular Cloning of Artemisinic Aldehyde Δ11(13) Reductase and Its Role in Glandular Trichome-dependent Biosynthesis of Artemisinin in Artemisia annua* , 2008, Journal of Biological Chemistry.
[56] Kyle T. Siebenthall,et al. Genome variation and evolution of the malaria parasite Plasmodium falciparum , 2007, Nature Genetics.
[57] Yi Mao,et al. Dynamical Basis for Drug Resistance of HIV-1 Protease , 2011, BMC Structural Biology.
[58] Drug discovery and developments in developing countries: bottlenecks and way forward. , 2006, Tanzania health research bulletin.
[59] Shigehiko Kanaya,et al. Metabolomics of medicinal plants: the importance of multivariate analysis of analytical chemistry data. , 2010, Current computer-aided drug design.
[60] Eric Arnoult,et al. The challenge of new drug discovery for tuberculosis , 2011, Nature.
[61] Manuel Llinás,et al. Comparative whole genome transcriptome analysis of three Plasmodium falciparum strains , 2006, Nucleic acids research.
[62] Yi Li,et al. The Genetic Map of Artemisia annua L. Identifies Loci Affecting Yield of the Antimalarial Drug Artemisinin , 2010, Science.
[63] E. Ernst,et al. Bringing medicinal plants into cultivation: opportunities and challenges for biotechnology. , 2005, Trends in biotechnology.
[64] H. Wagner,et al. Application of the "-Omic-" technologies in phytomedicine. , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[65] Richard Van Noorden. Demand for malaria drug soars , 2010, Nature.
[66] G. McVean,et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome , 2007, Nature Genetics.
[67] A. Okunade,et al. Natural antimycobacterial metabolites: current status. , 2004, Phytochemistry.
[68] James A. Eddy,et al. Accomplishments in genome‐scale in silico modeling for industrial and medical biotechnology , 2009, Biotechnology journal.
[69] H. Masum,et al. Accelerating Health Product Innovation in sub-Saharan Africa , 2007, Innovations: Technology, Governance, Globalization.
[70] J. Miller. The Discovery of Medicines from Plants: A Current Biological Perspective1 , 2011, Economic Botany.
[71] H. Wagner,et al. Synergy research: approaching a new generation of phytopharmaceuticals. , 2009, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[72] John C. Wootton,et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum , 2002, Nature.
[73] Eileen Kraemer,et al. PlasmoDB: a functional genomic database for malaria parasites , 2008, Nucleic Acids Res..
[74] A. Hamilton,et al. Medicinal plants, conservation and livelihoods , 2004, Biodiversity & Conservation.
[75] Craig M. Crews,et al. Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials , 2007, Cell.
[76] Peter H Seeberger,et al. Continuous-flow synthesis of the anti-malaria drug artemisinin. , 2012, Angewandte Chemie.
[77] P. Cox. The ethnobotanical approach to drug discovery: strengths and limitations. , 1994, Ciba Foundation symposium.
[78] J. Sachs,et al. The economic and social burden of malaria , 2002, Nature.
[79] T. Burkot,et al. Genetic analysis of the human malaria parasite Plasmodium falciparum. , 1987, Science.
[80] Bo Zhang,et al. Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.
[81] N. White,et al. Qinghaosu (Artemisinin): The Price of Success , 2008, Science.
[82] Liang Liu,et al. Network-based drug discovery by integrating systems biology and computational technologies , 2012, Briefings Bioinform..
[83] Santwana Kar,et al. Control of malaria , 1928, Nature Reviews Drug Discovery.
[84] Pardis C Sabeti,et al. A genome-wide map of diversity in Plasmodium falciparum , 2007, Nature Genetics.
[85] J. Keasling,et al. Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs. , 2007, The American journal of tropical medicine and hygiene.
[86] J. Keasling,et al. Engineering a mevalonate pathway in Escherichia coli for production of terpenoids , 2003, Nature Biotechnology.
[87] M. Garson,et al. Antitubercular constituents from the hexane fraction of Morinda citrifolia Linn. (Rubiaceae) , 2002, Phytotherapy research : PTR.
[88] S. Krishna,et al. Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.
[89] P. Arsenault,et al. Reproductive Development Modulates Gene Expression and Metabolite Levels with Possible Feedback Inhibition of Artemisinin in Artemisia annua1[C][W][OA] , 2010, Plant Physiology.
[90] N. Sangwan,et al. RAPD profile based genetic characterization of chemotypic variants of Artemisia annua L. , 1999, Biochemistry and molecular biology international.
[91] Bhushan Patwardhan,et al. Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? , 2009, Drug discovery today.
[92] S. Ambudkar,et al. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. , 2011, Current pharmaceutical biotechnology.
[93] V. Singh,et al. Kinetic modeling of tricarboxylic acid cycle and glyoxylate bypass in Mycobacterium tuberculosis, and its application to assessment of drug targets , 2006, Theoretical Biology and Medical Modelling.
[94] Abdul Jabbar,et al. Antimicrobial natural products: an update on future antibiotic drug candidates. , 2010, Natural product reports.
[95] D. Kwiatkowski. How malaria has affected the human genome and what human genetics can teach us about malaria. , 2005, American journal of human genetics.
[96] P. Clemons,et al. Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes , 2010, Journal of the American Chemical Society.
[97] N. Farnsworth,et al. The value of plants used in traditional medicine for drug discovery. , 2001, Environmental health perspectives.
[98] J. Stark,et al. Systems biology of persistent infection: tuberculosis as a case study , 2008, Nature Reviews Microbiology.
[99] Tatiana Nikolskaya,et al. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. , 2004, Drug discovery today.
[100] Jonathan Crabtree,et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax , 2008, Nature.
[101] O. Potterat,et al. Concepts and technologies for tracking bioactive compounds in natural product extracts: generation of libraries, and hyphenation of analytical processes with bioassays. , 2013, Natural product reports.
[102] S. Meshnick,et al. Artemisinin: mechanisms of action, resistance and toxicity. , 2002, International journal for parasitology.
[103] Jon Cohen,et al. Infectious disease. Approval of novel TB drug celebrated--with restraint. , 2013, Science.
[104] C. Buell,et al. Bioinformatics challenges in de novo transcriptome assembly using short read sequences in the absence of a reference genome sequence. , 2013, Natural product reports.
[105] John W. Erickson,et al. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase , 1995, Nature Structural Biology.
[106] Michael A Fischbach,et al. Natural products version 2.0: connecting genes to molecules. , 2010, Journal of the American Chemical Society.
[107] S Brindha,et al. Informatics resources for tuberculosis--towards drug discovery. , 2012, Tuberculosis.
[108] D. Guo,et al. Global characterization of Artemisia annua glandular trichome transcriptome using 454 pyrosequencing , 2009, BMC Genomics.
[109] Yi Wang,et al. Discovering active compounds from mixture of natural products by data mining approach , 2008, Medical & Biological Engineering & Computing.
[110] William F Reynolds,et al. Using NMR to identify and characterize natural products. , 2013, Natural product reports.
[111] S. Aljunid,et al. Development of health biotechnology in developing countries: can private-sector players be the prime movers? , 2012, Biotechnology advances.
[112] N. Day,et al. Artemisinin resistance: current status and scenarios for containment , 2010, Nature Reviews Microbiology.
[113] George M Church,et al. Tuberculosis Drug Resistance Mutation Database , 2009, PLoS medicine.
[114] Lie-Fen Shyur,et al. Metabolomics for phytomedicine research and drug development. , 2008, Current opinion in chemical biology.